GenAI drug discovery company VantAI has forged a strategic collaboration with Bristol Myers Squibb (BMS) to develop new molecular glues for various therapeutic targets.
As part of the agreement, VantAI is eligible to receive up to USD 674 million as discovery, development, clinical, regulatory, and sales milestone payments, as well as specific, tiered royalty payments. The agreement also enables the option to broaden the partnership to more therapeutic programs from BMS.
The collaboration will combine VantAI's geometric deep learning technologies and BMS’ protein degradation expertise to develop molecular glues, which help stabilize the interaction between two proteins.
Founded in 2019, VantAI integrates GenAI with drug discovery to develop computational models that reveal hidden connections between molecules, targets, and diseases, thereby making protein interactions programmable. The company uses geometric deep learning platforms to focus on induced proximity modulators, which are designed to unlock the full potential of proximity modulator modalities for drug discovery.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.